Caplin Point Laboratories Ltd has been recognized in Forbes Asia’s 200 Best Under a Billion list for the year 2023, a compilation that underscores companies’ sustained and robust performance across critical benchmarks. Carefully selected from a substantial pool of more than 20,000 publicly traded companies across the Asia-Pacific region, the chosen 200 enterprises showcase annual sales under $1 billion. The comprehensive criteria encompasses evaluation of debt management, sales growth, earnings-per-share performance, as well as returns on equity
Commenting on the achievement, Mr. C.C. Paarthipan, Chairman said: “The inclusion of Caplin Point Laboratories Ltd in Forbes Asia’s ‘200 Best Under a Billion’ list for 2023 is a testament to our dedication to excellence. This marks our 6th appearance on this list in the last decade—a prestigious achievement for an Indian pharmaceutical company. We remain focused on strengthening cash flows and ensuring consistent profitability and this recognition reaffirms our commitment to these financial goals.”